New study results presented at ASCO supports DiviTum® for monitoring advanced breast cancer treatment
The EFECT-study evaluated standard hormonal therapies for women with advanced breast cancer and DiviTum® was used as a non-invasive tool for monitoring therapy response. 244 patients had blood samples analyzed with DiviTum® in a collaboration between AstraZeneca, Prato Hospital, Italy, Institute Jules Bordet, Belgium, British Columbia Cancer Agency, Canada and Biovica, Sweden.
DiviTum® measures the activity of serum thymidine kinase (TK) activity which plays a critical role in DNA synthesis and cell proliferation. The study found that serum TK is a circulating prognostic and monitoring marker in patients with advanced breast cancer treated with hormonal therapy. By evaluating levels of TK during treatment DiviTum® can provide important information for treating physicians. Patients resistant to on-going hormonal therapies can be identified, enabling alternative treatment options.
The ASCO (American Society of Clinical Oncology) annual meeting taking place June 1-5 in Chicago is the largest scientific cancer congress in the world (40 thousand participants in 2017).
“Endocrine therapy is the treatment of choice for patients with metastatic breast cancer expressing hormone receptors; however, as clinicians, we currently do not have tools to early identify those patients who will do good with endocrine therapy alone or may need additional treatment. The results from our work with DiviTum are exciting and confirm in a larger number of patients our previous observation that this assay may indeed help clinicians in this hard task. DiviTum will certainly become a very useful tool for the development of innovative clinical trials in this field, and ultimately for clinical practice”. – says Dr Luca Malorni, MD, PhD, Prato Hospital, Italy.
“These results reinforce what we have seen in previous studies, proving that DiviTum® can provide clinically relevant information highly beneficial for women with advanced breast cancer on hormonal therapy.” – says Anders Rylander, CEO Biovica and continues,”We are convinced that bringing products like DiviTum® to the market will contribute to bringing the best possible treatment for cancer patients.”
Malorni L et al, ASCO Annual Meeting 2018; abstract #12031
http://abstracts.asco.org/214/AbstView_214_219453.html
More information:
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
E-mail: anders.rylander@biovica.com
This information is information that Biovica International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person(s) set out above, at 09.15 CET on May 17, 2018.
About Biovica
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.
Read more: www.biovica.com
Tags:
